Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins.

CONCLUSIONS: Although no independent survival benefit was observed, the point estimates favoured adjuvant treatment, predominantly in patients with chemo-responsive tumours. PMID: 33586602 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33586602?dopt=Abstract

Source: Acta Oncologica - February 15, 2021 Category: Cancer & Oncology Authors: Bott RK, Beckmann K, Zylstra J, Wilkinson MJ, Knight WRC, Baker CR, Kelly M, Maisey N, Waters J, Van Hemelrijck M, Smyth EC, Allum WH, Lagergren J, Gossage JA, Cunningham D, Davies AR Tags: Acta Oncol Source Type: research